isoxazoles has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bubl, B; Feuerstein, TJ; Hubbe, U; Huethe, F; Jackisch, R; Löffler, M; McIntosh, JM | 1 |
| Araki, T; Kato, H; Kuroiwa, H; Yano, R; Yokoyama, H | 1 |
| Choudhury, ME; Kubo, M; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H | 1 |
| Araki, T; Kasahara, J; Kato, H; Kuroiwa, H; Tsukada, T; Uchida, H; Yano, R; Yokoyama, H | 2 |
| Hattori, N; Kawajiri, S; Machida, Y; Saiki, S; Sato, S | 1 |
6 other study(ies) available for isoxazoles and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adolescent; Adult; Aged; Alkaloids; Analysis of Variance; Animals; Autoreceptors; Azocines; Calcium; Child; Child, Preschool; Domperidone; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Feedback; Female; Fluvoxamine; Humans; In Vitro Techniques; Isoxazoles; Male; Maprotiline; Mice; Middle Aged; Neocortex; Nicotine; Nicotinic Antagonists; Potassium; Pyrrolidines; Quinolizines; Rats; Receptors, Nicotinic; Sulpiride; Time Factors; Tritium | 2006 |
A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Astrocytes; Corpus Striatum; Dopamine; Glial Fibrillary Acidic Protein; Homovanillic Acid; Isoxazoles; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neurons; Neuroprotective Agents; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase; Zonisamide | 2009 |
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsants; Biogenic Amines; Brain Chemistry; Callithrix; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Homovanillic Acid; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neostriatum; Neurons; Selegiline; Zonisamide | 2009 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Dopamine; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Treatment Outcome; Zonisamide | 2010 |
Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antioxidants; Apoptosis; Caspases; Cell Differentiation; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; In Situ Nick-End Labeling; Isoxazoles; Neuroblastoma; Neurotoxins; Staurosporine; Superoxide Dismutase; Up-Regulation; Zonisamide | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Dopamine; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Treatment Outcome; Zonisamide | 2010 |